Floatz logo

Maridebart Cafraglutide

Obstructive Sleep Apnea

Amgenantibody_drug_conjugatePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Obstructive Sleep Apnea cohort.

Asset / SponsorPhaseRating
LEVODOPA
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 4BB
NEOSTIGMINE
University Health Network, Toronto
Phase 4BB
Sibutramine
Laval University
Phase 4BB
carbidopa
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 4BB
.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO-
University Health Network, Toronto
Phase 4BB

View all 33 →

Same molecule, other indications

Maridebart Cafraglutide is also rated in:

atherosclerotic cardiovascular diseaseDormant
B
Indicative ·
60 / 100
View asset →
obesity disorderDormant
B
Indicative ·
60 / 100
View asset →
Type 2 Diabetes Mellitus (T2DM), Obesity, OverweightDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →